Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Mechanism of action of fibrates on lipid and lipoprotein metabolism.

Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC.

Circulation. 1998 Nov 10;98(19):2088-93. Review.

2.
3.

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.

Schoonjans K, Staels B, Auwerx J.

Biochim Biophys Acta. 1996 Jul 26;1302(2):93-109. Review.

PMID:
8695669
4.

[Mechanisms of actions of statins and fibrates].

Duriez P.

Therapie. 2003 Jan-Feb;58(1):5-14. Review. French.

PMID:
12822195
5.
6.
7.

Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.

Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, Fievet C, Auwerx J, Staels B.

Arterioscler Thromb Vasc Biol. 1997 Sep;17(9):1756-64.

8.

Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

Fruchart JC, Duriez P.

Drugs Today (Barc). 2006 Jan;42(1):39-64. Review.

PMID:
16511610
9.

Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil.

Dallongeville J, Baugé E, Tailleux A, Peters JM, Gonzalez FJ, Fruchart JC, Staels B.

J Biol Chem. 2001 Feb 16;276(7):4634-9. Epub 2000 Oct 24.

10.

The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates.

Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, Laudet V, Staels B.

J Biol Chem. 1998 Oct 2;273(40):25713-20.

11.

[Molecular mechanism of action of the fibrates].

Fruchart JC, Duriez P, Staels B.

J Soc Biol. 1999;193(1):67-75. Review. French.

PMID:
10851558
12.

Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects.

Auwerx J, Schoonjans K, Fruchart JC, Staels B.

J Atheroscler Thromb. 1996;3(2):81-9. Review.

PMID:
9226459
13.

Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation.

Andersson Y, Majd Z, Lefebvre AM, Martin G, Sechkin AV, Kosykh V, Fruchart JC, Najib J, Staels B.

Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):115-21.

14.

Fibric acids: effects on lipids and lipoprotein metabolism.

Grundy SM, Vega GL.

Am J Med. 1987 Nov 27;83(5B):9-20. Review.

PMID:
3318457
15.

A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor.

Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S, Leff T, White AD, Creger P, Pape ME, Rea TJ, Newton RS.

J Lipid Res. 1998 Jan;39(1):17-30. Erratum in: J Lipid Res 1998 Jun;39(6):1317.

16.

Regulation of lipid and lipoprotein metabolism by PPAR activators.

Gervois P, Torra IP, Fruchart JC, Staels B.

Clin Chem Lab Med. 2000 Jan;38(1):3-11. Review.

PMID:
10774955
17.

[Anti-cholesterol agents, new therapeutic approaches].

Fruchart JC, Duriez P.

Ann Pharm Fr. 2004 Jan;62(1):3-18. French.

PMID:
14747768
18.

Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice.

Mardones P, Pilon A, Bouly M, Duran D, Nishimoto T, Arai H, Kozarsky KF, Altayo M, Miquel JF, Luc G, Clavey V, Staels B, Rigotti A.

J Biol Chem. 2003 Mar 7;278(10):7884-90. Epub 2003 Jan 2.

19.

Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Després JP, Lemieux I, Robins SJ.

Drugs. 2004;64(19):2177-98. Review.

PMID:
15456334
20.

Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo.

Guo L, Hu WR, Lian JH, Ji W, Deng T, Qian M, Gong BQ.

Eur J Pharmacol. 2006 Dec 3;551(1-3):80-6. Epub 2006 Sep 6.

PMID:
17026988
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk